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Abstract
Emerging results indicate that screening improves survival of patients with colorectal cancer. Therefore, screening programs
are already implemented or are being considered for implementation in Asia, Europe and North America. At present, a great
variety of screening methods are available including colono- and sigmoidoscopy, CT- and MR-colonography, capsule
endoscopy, DNA and occult blood in feces, and so on. The pros and cons of the various tests, including economic issues,
are debated. Although a plethora of evaluated and validated tests even with high speciﬁcities and reasonable sensitivities are
available, an international consensus on screening procedures is still not established. The rather limited compliance in present
screening procedures is a signiﬁcant drawback. Furthermore, some of the procedures are costly and, therefore, selection
methods for these procedures are needed. Current research into improvements of screening for colorectal cancer includes
blood-based biological markers, such as proteins, DNA and RNA in combination with various demographically and clinically
parameters into a “risk assessment evaluation” (RAE) test. It is assumed that such a test may lead to higher acceptance among
the screening populations, and thereby improve the compliances. Furthermore, the involvement of the media, including social
media, may add even more individuals to the screening programs. Implementation of validated RAE and progressively
improved screening methods may reform the cost/beneﬁt of screening procedures for colorectal cancer. Therefore, results of
present research, validating RAE tests, are awaited with interest.
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Colorectal cancer (CRC) represents a major public
health problem accounting for more than one million
new cases and approximately half a million deaths
worldwide every year [1]. At primary diagnosis 80%
of the patients will undergo intended curative resec-
tion, but 40–45% of these patients will develop
recurrent disease within the next 5 years [2,3],
most often leading to fatal outcome. Presently, at
the time of diagnosis half of the patients have stage I
or II disease, and the other half have disseminated
disease, stage III or IV. It is assumed that overall
survival would be substantially improved if more
patients were detected and diagnosed at an early
stage [4,5]. Such a hypothesis is supported by the
fact that population screening for CRC using fecal
occult blood test (FOBT) results in more individuals
being diagnosed with an early-stage disease [6,7],
which translates into improved survival compared to
CRC cases not detected by screening [8–10]. Recent
reports suggest that screening procedures may even
reduce the incidence of CRC due to detection and
removal of precancerous lesions [11,12]. Therefore,
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reduce incidence and improve survival [13,14].
Justifying screening for CRC
The following factors justify screening for CRC:
. The disease causes signiﬁcant morbidity and
mortality
. Treatment of the disease is a ﬁnancial burden for
the society
. The disease is detectable in an asymptomatic stage
. The disease can be prevented with intervention at
the premalignant stage
. Effective treatment modalities are present for early
stages
. Higher survival rates among patients detected by
screening
. Early detection carries beneﬁts for the patient
. Early detection carries beneﬁts for the society
Who should be offered screening?
The incidence of CRC is age-related with a median
age of 70 years [15] and the lower quartile at the age of
58. Current studies of screening and implemented
screening programs for the average risk population
include, with few exceptions [16], individuals in the
age range of 50–75 years [17]. It is currently suggested
that screening offers must be extended to individuals
between 40 and 85 years of age [18], due to ﬁndings
that signiﬁcant proportions of individuals between
40 and 50 years have large bowel neoplastic lesions,
combined with the fact that overall lifetime expec-
tancy is increasing. Feasibility and subsequent success
in screening programs may lead to debate on the
suggested extension of the hitherto agreed age
intervals.
Present methods for CRC screening
Colonoscopy is still considered the gold standard for
detection of neoplastic large bowel lesions. The pro-
cedure allows examination of the entire large bowel
with ability to biopsy lesions and even to remove most
adenomas within the same sequence. The procedure
is used either as an examination without any pretest,
or in combination with FOBT and/or ﬂexible sig-
moidoscopy. Colonoscopy is also used subsequent
to capsule-, CT- or MR-colonography, where
detected lesions can be excised colonoscopically.
Direct colonoscopy
The procedure is widely used for screening particu-
larly in the USA. Due to improvements in the US
Medicare system the number of individuals screened
by colonoscopy without any pretest has increased
since 2008 [19]. Improved referral programs among
primary care practitioners in the USA have led to
procedures where low-risk individuals might undergo
direct colonoscopy without the need for a preconsul-
tation visit at the endoscopists’ clinic [19]. However,
direct colonoscopy is still an expensive screening
procedure: First, colonoscopy requires complete
bowel preparation, which must be initiated 2–3
days before the procedure. Second, current medica-
tions must be taken into account among some indi-
viduals whereas patients with diabetes need speciﬁc
attention and preparation; some may even be hospi-
talized. Third, at least one day off work — the day
before a colonoscopy procedure – may be expected
due to bowel evacuation. Furthermore, most indivi-
duals need sedation during colonoscopy, which leads
to an additional half or whole day off work, and often a
third person has to take care of the transport back
from the clinic. In total, an individual who undergoes
colonoscopy is completely out of work or daily rou-
tines for 1.5–2 days. The sum of all these costs added
to the costs of the colonoscopy procedure causes
major expenses [20]. Finally, colonoscopy may lead
to adverse events such as cardiopulmonary incidents
(1.1%), bleeding (0.16%), perforation (0.09%) and
death (0.007%) [21].
Although screening by colonoscopy may secure
detection of the majority of all bowel lesions, the
procedure is still not an option for general population
screening because of the fact that no society has either
the capacity or the ﬁnancial resources to offer the
procedure to all its citizens. The costs of the proce-
dure are approximately 1000–1200 USD per individ-
ual, even without inclusion of the costs of recovery
and 1.5–2 days off work or daily routines. Adverse
events add even more costs to the procedure. Offering
colonoscopy to individuals between 50 and 75 years of
age, for instance, every 10th year would require an
examination capacity for about 250 million. indivi-
duals in Europe and North America alone. Thus, the
cost-beneﬁt of a model primarily based on colonos-
copy has to get signiﬁcantly improved.
Colonography and capsule endoscopy
CT-colonography (CTC) could be an attractive, non-
invasive tool to visualize the entire bowel and thereby
identify lesions in the bowel wall. Obviously, this
approach may be of advantage among persons where
colonoscopy is not feasible either due to personal
resistance or due to known diverticulosis, where pas-
sage even with a thin colonoscope is cumbersome. An
additional advantage of CTC is detection of
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its disadvantages; the procedure still requires metic-
ulous bowel evacuation and air insufﬂation of the
bowel. In addition, lesions <6m m ,ﬂat adenomas
or adenocarcinomas appear to be missed [24]. Finally
detected lesions require subsequent colonoscopy or
sigmoidoscopy for excision purposes. Moreover, the
CTC-associated radiation burden is high and should
be considered among the disadvantages of the pro-
cedure, particularly among persons undergoing
repeated screening procedures. Even detection of
extracolonic lesions may be of potential disadvan-
tages, because such lesions may add further examina-
tions to the ongoing procedures. Most of such lesions
turn out to be benign and do not carry any signiﬁcant
risks [22].
Whether CTC would increase the compliance rates
in screening programs compared with colonoscopy is
presently unknown; also, the cost-effectiveness of
CTC is yet to be established. The aims in a current
Dutch study on 7,500 persons in the age range of
50–75 years include compliance, yield and costs. The
persons are randomized to either CTC (one-third) or
colonoscopy (two-thirds), and, in addition, the need
for pre-endoscopy consultations is also studied [25].
A recent report, though, based on models using four
different technologies, namely, FOBT, ﬂexible sig-
moidoscopy, colonoscopy and CTC, have estimated
lifetime costs and outcomes of a cohort of persons
screened at 60–69 years of age [26]. The report
concluded that the use of CTC every 10th year has
a potential to be as cost-effective as biennial FOBT
screening [26]. However, these results need to be
veriﬁed in sufﬁciently powered clinical trials before
CTC is considered a preferable procedure in screen-
ing for CRC.
Compared to CTC, MR-colonography (MRC),
which is also a non-invasive procedure, may have
the advantage of being free from the risk of radiation
damages. Furthermore, new techniques with fecal
tagging have signiﬁcantly reduced the need for bowel
evacuation [27,28], and also the acceptability seems
to be an advantage of MRC compared to colonoscopy
[28]. It appears, though, that MRC technology may
not detect lesions <6–10 mm [29], and a colonoscopy
will still be required in most cases of detected lesions.
Additional research is urgently needed to evaluate the
cost-effectiveness of the MRC procedure as general
population screening. Presently, it is not likely that
MRC will be recommended for screening.
Endoscopy using bowel cameras in large capsules
might be a future option, and the yield may be
comparable with CTC and MRC. However, meticu-
lous bowel evacuation and subsequent colonoscopy or
ﬂexible sigmoidoscopy will also be needed in those
persons where lesions are detected. Still sufﬁciently
powered studies are needed to evaluate this approach
in comparison with other presently available and
accepted procedures.
Flexible sigmoidoscopy
Approximately 70–75% of the neoplastic large bowel
lesions are located in the rectum and left colon. The
bowel preparation for sigmoidoscopy is signiﬁcantly
less compared with the preparation for colonoscopy:
Rigid fast of solid foods from midnight the day before
sigmoidoscopy and a small cleansing enema taken
1–2 h before sigmoidoscopy often sufﬁciently leads
to evacuation of the left-sided bowel. These facts
justify approaches for screening procedures using
ﬂexible sigmoidoscopy. The fact that this procedure
does not require any pre-test may lead to a high
patient acceptance and thereby an acceptable com-
pliance [30,31]. The approach mediates reduction of
the incidence and mortality of CRC [30,31], partic-
ularly of the left-sided tumors. Although a UK-based
randomized study [31] showed reduction of mortality
due to tumors anywhere in the colonic bowel, most
studies have shown that transverse and right-
sided lesions are missed [32–34] even when combined
with a subsequent FOBT [32]. These results plus
those from a Norwegian study [30] raise the question
of whether sigmoidoscopy should be recommended in
place of colonoscopy for future screening procedures,
or at least considered an option comparable to colo-
noscopy for individuals offered screening for CRC
[35–37]. A recent Canadian case-control study
showed that colonoscopy led to reduction in mortality
of left-sided lesions, but similar reduction could not
be shown for right-sided lesions [38]. Such results
may add power to sigmoidoscopy, but subsequent
discussion awaits results from current randomized
studies, including those on colonoscopy, showing
whether the supposed beneﬁts of the sigmoidoscopy
procedure can be conﬁrmed [37].
Fecal occult blood tests
FOBT screening has shown its ability to reduce
mortality resulting from CRC [6–11] and several
countries have implemented or are considering imple-
menting the procedure for general population screen-
ings. The speciﬁcity of the various tests is around
85–90%, while the sensitivity of the tests has a wide
range of 40–90%. Results from a variety of studies
have shown, however, that compliance varies between
30% and 85%. These ﬁgures are notable, because lack
of compliance leads to signiﬁcantly limited clinical
sensitivity (test sensitivity X compliance), that is,
between 12% and 76%. Consequently, a signiﬁcant
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fore, exploration of the mechanisms leading to rejec-
tion of the offer of FOBT screening is needed in order
to improve the procedure. Otherwise investments in
such screening programs may be unsuccessful and
turn out to have limited value.
In general there are two different FOBT tests: the
guaiac (G-FOBT) and the immunologic (FIT).
Patient preparation for the G-FOBT is extensive
and includes a variety of drugs and diets that must
be omitted. Thus, for a period of 7 days before the
stool-sampling period, patients must not use
NSAIDs and many other similar drugs, because
these may lead to false positive results of the G-
FOBT. Also, 3 days before stool-sampling, patients
should avoid red meat (lamb, beef and liver), and
24 h before the test sampling, they must refrain from
alcohol, aspirin and vitamin C [11]. Next step –
stool-sampling – m a yb eac o m p l i c a t e dm a n e u v e r
for many persons; the procedure requires the indi-
vidual to deal with his or her feces in three conse-
cutive collections. The samples must be transferred
to the provided cards, dried and mailed. If the test
results are positive, the patient is assumed to be at
risk of having a neoplastic lesion in the large bowel
and is, therefore, offered subsequent colonoscopy
and/or other complete diagnostic evaluation proce-
dures. Surprisingly, many such at-risk persons are
not willing to undergo diagnostic evaluation, includ-
ing colonoscopy (in some studies 40–65%). Mere
patient refusal, high age, young age or persons with-
out insurances often explaint h er e f u s a l s ;l a c ko f
insurance is a particular limiting phenomenon in
the US [39–41].
Nevertheless, emerging results have shown that the
number of patients detected with stage I or II diseases
by FOBT is signiﬁcantly increased, while the number
with stage IV diseases is decreased [11]. Thus in a
recent Danish feasibility study [42] with 177,148 per-
sons between 50 and 74 years of age, 85,374 persons
returned their test card to the study centers (compli-
ance 48.2%). Positive test results were shown in
2,085 persons, who were offered subsequent colonos-
copy. Among these, polyps were detected in 841 and
CRC in 174 persons (ppv for CRC = 8.3%). The
CRC diagnoses among the screened persons were
stage I: 36.8% [Danish Colorectal Cancer Group
(DCCG) data on all Danish CRC cases [43] was
12.5%]; stage II: 27.6% (DCCG data, 33.2%); stage
III: 27.0% (DCCG data, 28.6%); and stage IV: 8.0%
(DCCG data, 21.2%). These data from the Danish
feasibility study [42] are similar to data from other
international screening protocols and indicate that
screening substantially identiﬁes cancer patients at
an early stage, and through this improves the chances
for complete resection of more patients than in non-
screening populations [11,44–45].
Introduction of the FIT test has led to an improved
pre-sampling preparation procedure. Using enzy-
matic reactions [46] the test was developed to detect
human hemoglobin, and thereby the need for dietary
restrictions (i.e., red meat and various drugs) before
stool-sampling was performed [47]. Therefore, as
expected [11], both compliance and ppv and npv
rates were substantially improved [48], particularly
for CRC [46] but also for adenomas [49,50]. Results
of FIT screening procedures and subsequent colo-
noscopy on mortality have yet not been reported, but
are awaited with interest. Comparisons of perfor-
mances of G-FOBT and FIT have demonstrated
an increased sensitivity of FIT both for CRC and
adenoma detection [48,49,51–52]. If FIT screening
procedures improve the mortality of CRC, these
particular tests should be recommended for future
screenings for adenoma and CRC instead of G-
FOBT screening.
Fecal DNA tests
Development of neoplastic lesions in the large bowel
appears to be based on hereditary genetic syndromes
in 5–10% of the cases, while sporadic neoplastic
lesions based on gene mutations appear in 90–95%
of the cases. The progression from precursor lesions
over benign to malignant lesions seems to be due to
sequential genetic changes [53]. Because of exfolia-
tion, cellular elements containing genetic information
on these genetic changes are mixed and shed with the
stools. This observation led to development of various
assays for DNA identiﬁcation procedures in stools,
and the procedure appears to be a feasible option for
detection of neoplastic lesions in screening for CRC
[54,55]. However, the accuracy of the test does seem
comparable to the G-FOBT tests. The costs, though,
are 30-fold higher than the costs for G-FOBT and
10-fold higher than those for FIT [11]. In addition to
the costs, the stool-sampling procedures are needed to
be focused upon as well. Stool-sampling for the DNA
tests includes a plastic bucket that is mounted onto
the toilet. The whole bowel excretion must be col-
lected without contamination by urine or toilet paper.
The bucket is subsequently transferred to a cooling
device and shipped by mail to a given reference
laboratory. Once in the laboratory stools are homog-
enized and treated with RNase, followed by puriﬁca-
tion and real-time polymerase chain reaction using
target speciﬁc primers, all of which is a rather com-
plicated procedure. Therefore, DNA stool testing is
expected to have only limited impact on overall future
screening procedures.
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At present the variety of tests and procedures for
screening for CRC appears challenging for the health
authorities and in particular for the health budgets.
General implementation of the gold standard – colo-
noscopy – for all persons between 50 and 74 years of
age would require a capacity to screen 250 million.
individuals over a 10-year period in Europe and North
America. The frequency would certainly be increased
in those persons with precancerous lesions, and
thereby more individuals must undergo colonoscopy
per year. As no nation would have such resources and
capacity available, we need to focus on selection
procedures (prescreening) for colonoscopy, which
could, for instance, be tests for occult blood in feces.
Among these tests, the results by FIT screening are
compelling. Using FIT screenings may be the deﬁn-
itive choice, if emerging results of using this model
show reduced mortality by CRC. In spite of high
speciﬁcities and fair sensitivities in all available tests
for occult blood and DNA in feces [11] , the limited
compliance rates may be the major hindrance in using
such tests for present and future general screening
procedures. Often compliance rates are as low as
between 40% and 50%. Thereby the clinical sensi-
tivity is substantially reduced leaving many persons
with unknown neoplastic lesions.
Refusal of participation in prescreening procedures
and subsequently in colonoscopy among a substantial
number of persons with positive FOBT or FIT tests
may lead to considerations of at least three alterna-
tives: (1) offering other diagnostic tests such as, for
instance, MR- or CT-colography; (2) development of
a prescreening tests with improved positive predictive
value (ppv) and negative (n)pv and/or; (3) major
media campaigns focusing on the subject. The Amer-
ican Society of Colon and Rectal Surgeons have
recently recognized the signiﬁcance of proper media
coverage on CRC screening by giving awards to three
reporters [56] who made a substantial effort in cov-
ering the subject.
Future prescreening test options
Among future options for screening procedures are
implementation of blood tests for proteins and genes
related to CRC and possibly to adenomas. Carci-
noembryonic antigen (CEA) in serum was the ﬁrst
soluble biomarker accepted for use in CRC and is still
the only recommended soluble biomarker being pri-
marily used for monitoring purposes. However, the
level of CEA is strongly dependent of the stage of
disease with a low positive rate in early-stage disease
and a high positive rate in late-stage disease.
Therefore, the sensitivity of CEA in screening varies
between 8% and 89% at speciﬁcities of 70–95% [57].
The latest American Society for Clinical Oncology
(ASCO) guidelines accordingly recommend that
CEA is not used as a single screening test for CRC
[58].
Plasma tissue inhibitor of metalloproteinases-1
(TIMP-1) has been suggested for early detection of
CRC [59–61], as high plasma TIMP-1 levels were
shown to identify colon cancer (CC) patients with a
sensitivity of 63% at 98% speciﬁcity, patients with
early CC (stage I and II) with a sensitivity of 56% at
98% speciﬁcity and patients with right-sided CC with
a sensitivity of 72% at 98% speciﬁcity [61]. The rates
for detection of RC are not as prominent. A subse-
quent study by independent investigators supported
that the plasma TIMP-1 protein level may be an
important marker in early detection of CRC showing
42% sensitivity at 95% speciﬁcity [62]. Of speciﬁc
interest was that the discrimination was signiﬁcantly
improved by combining TIMP-1 with CEA measure-
ments [61]. The previous studies used retrospectively
collected plasma samples from patients with known
CRC and healthy blood donors as control individuals.
Such approaches may introduce bias since blood
donors are not representative of a CRC-related back-
ground population. Another potential confounder in
such studies is that samples from patient cohorts and
healthy volunteers may not be collected simulta-
neously and, therefore, often not be according to
similar standard operating procedures (SOPs).
The tumor marker utility grading system
(TMUGS) guidelines [63] suggest that retrospec-
tively obtained results must be prospectively validated
in order for a biomarker to reach clinical acceptance
and subsequent implementation. Such prospective
studies should take all possible pre-, intra- and post-
analytical aspects into consideration, including the
use of strict and identical sampling, handling and
storage procedures for specimens from all recruited
individuals [64].
Thus a prospective, population-based validation
study including individuals scheduled for large bowel
endoscopy due to symptoms of CRC were initiated
[65]. The primary aim of the study, which included
4,509 individuals, was to validate the combination of
plasma TIMP-1 and CEA as biomarkers in early
detection of CRC. Overall the results supported the
fact that the combination of plasma TIMP-1 and CEA
was a valuable biomarker in early detection of the
disease, speciﬁcally of CC [66]. It was also demon-
strated that both plasma TIMP-1 and CEA levels
were signiﬁcantly increased in individuals without
CRC, but diagnosed with a variety of non-malignant
diseases including diabetes I or II, bronchitis, asthma,
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vascular and liver diseases [66]. The compliance of
the study was 96.8%; it should be kept in mind
however, that the individuals had symptoms of
CRC and as such were at-risk individuals, who
were admitted for examination of the large bowel.
Subgroups of samples were used to identify possible
new biomarkers that might be used for early detection
of CRC either as single markers or in various combi-
nations of markers. One group included 77 samples
collected from individuals who turned out to have
CRC, and a second group consisted of 77 samples
from age- and gender-matched individuals with ade-
noma at the same location as the CRC lesions. A third
group were 77 samples collected from individuals
with other non-malignant GI ﬁndings (diverticulosis)
and the fourth group included samples from 77 indi-
viduals with no ﬁndings and no concurrent disease
(n = 308 in total). At present, the liberated domain I of
the urokinase receptor suPAR(I) in plasma appears to
have the potential as a biomarker in CRC [67–69] and
might be useful in early detection [67]. Results from a
variety of other potential biomarkers, including pro-
teins, miRNAs, and SNPs, are awaited.
All achieved results from studies of plasma
TIMP-1 and CEA [61,62,66] are comparable with
the emerging results of Septin 9 (SEPT9) regarding
sensitivity and speciﬁcity for CRC detection. SEPT9
determinations represent a marker of hypermethyla-
tion in DNA extracted from plasma collected from
patients with known CRC and plasma from a variety
of healthy and non-cancerous control individuals
[70,71]. Results with SEPT9 have very recently
been conﬁrmed in a population-based, prospective
study on 7,940 individuals admitted to screening for
CRC [72]. In this particular study all individuals had
plasma collected before colonoscopy, which identiﬁed
53 individuals with CRC. The sensitivity of the
SEPT9 test was 66.7% at 88.4% speciﬁcity. The
company behind the test suggests that the SEPT9
test is the future prescreening test, and that screened
persons may be veryconﬁdent with a negative result of
the test due to its npv of 99.7% [72]. As with plasma
TIMP-1 and CEA, SEPT9 also identiﬁes individuals
with a variety of other diseases than CRC, a fact that
must be considered also among CRC patients, who
may have one or more of these diseases in addition to
CRC. A future option might be to evaluate the com-
bination of plasma SEPT9 with plasma TIMP-1 and
CEA. Such combined results may lead to a higher
performance in detection of CRC and possibly also
precancerous lesions among individuals without
symptoms [66,73].
Summarizing all the facts presented here leads to
the conclusion that no single test appears to have an
acceptable ppv, and the various tests identify indivi-
duals with diseases other than CRC or adenoma.
Therefore, a usable option could be to establish a
risk assessment evaluation (RAE) test. Such a test is to
be based on demographic and clinical parameters [74]
in combination with various blood tests of proteins,
gene polymorphisms, methylated genes, microRNAs
and so on. It is well known that age, gender, race and
BMI, plus a variety of diseases, carry a higher risk of
developing CRC ([75–98], Table I). Alcohol con-
sumption has been suggested as an additional risk
factor [95], but recent results could not support this
suggestion [99–101]. Therefore, alcohol consump-
tion should presently not be included in a RAE test.
Possible RAE model
Figure 1 represents a RAE based on the results from
the recent, aforementioned study on early detection of
CRC in a high-risk population [66]. The study
showed that age and gender were independent pre-
dictors of CRC, and that co-morbidities inﬂuenced
the signiﬁcance of both plasma TIMP-1 and CEA
levels. For example, plasma TIMP-1 levels as well as
plasma CEA levels in an individual with co-
morbidity will often be higher than in an individual
without co-morbidity. The exampled normogram
based on such tests for individuals aged 70–80 years
adjusted for gender and co-morbidity is shown
in Figure 1. Choosing a probability of 15% for
CRC as a cut-point in this high-risk population, a
test based on these covariates had a speciﬁcity of 94%
with a sensitivity of 43%. A male without co-
morbidity with plasma TIMP-1 and CEA co-
ordinates to the right of the dotted blue line would
be considered positive for this RAE test. Similarly, a
male with co-morbidity would only be considered
positive for this RAE test if the co-ordinates of his
plasma TIMP-1 and CEA levels fall to the right of the
solid blue line. A female with or without co-
morbidity and with plasma TIMP-1 and CEA co-
ordinates to the right of the solid red or the dotted red
line, respectively, would be considered positive for the
Table I. Increased risk of developing colorectal neoplasia is
associated with the following factors
Age 75,76
Gender 77,78
Race 79,80
BMI 81,82
Smoking habits 78,83,84,85
Inﬂammatory bowel disease 86,87,88
Diabetes type II 89,90,91,92,93
Familial disposition 94,95
Hereditary disposition 96,97,98
1288 H. J. Nielsen et al.test. Conclusively, individuals with positive test
results must be offered colonoscopy for further diag-
nostic purposes. Thus using this RAE test can be
beneﬁcial as a prescreening and selection test.
It is urgent to identify valid biological markers with
high ppvs and npvs to be included into a RAE test. At
present, a major (>5,000 individuals) study on vali-
dating the suggested RAE combined with demo-
graphic, clinical and biomarker parameters is being
performed across Denmark. Simultaneously, various
biomarkers are identiﬁed [73,102–110] and must be
evaluated and validated to be included into the RAE.
In the event that the RAE passes this validation, new
biomarkers can be included, whenever they pass the
TMUGS guidelines [63]. Thereby the RAE test can
be progressively improved [111].
There are several beneﬁts of instituting RAE tests
for prescreening of CRC. First of all this test can be
completed whenever needed. When a single individ-
ual in conjunction with his or her practitioner has
performed the basic RAE test once, the subsequent
calculation could be performed online. Next time the
individual only has to leave a blood sample for testing,
and the subsequent results can be added into the
online calculation sheet. Changes in scores will
then work as a guide for further examinations includ-
ing colonoscopy. Second, by using an easily available
prescreening test as the RAE test, compliance can be
improved substantially through supportive media
campaigns, even using electronically available tech-
nology such as social medias, automated telephone
calls and text messages [112,113]. Moreover, the fact
that all individuals follow their risk scores on their
own might reduce the refrain from undergoing sub-
sequent colonoscopy [39–41]. In cases where indivi-
duals still refuse to undergo colonoscopy, they might
be offered either a subsequent FIT test to further
encourage colonoscopy or direct CT- or MR-
colonography with subsequent colonoscopy/resec-
tion, if lesions are detected.
It has been argued, however, that screening proce-
dures may lead to anxiety among some individuals,
particularly when results are awaited over days. But
results from a recent population-based study on psy-
chological distress following FOBT screening could
not demonstrate any adverse effect on psychological
well-being [114].
In summary, we are conﬁdent that CRC screening
can be appreciably improved. Particularly, an imple-
mentation of validated RAEs might improve compli-
ance and thereby lead more individuals to a
subsequent large bowel examination. Therefore, the
results of ongoing studies in Europe and USA are
awaited with interest.
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Figure 1. A male without co-morbidity with plasma TIMP-1 and CEA co-ordinates to the right of the dotted blue line would be considered
positive for this test. Similarly, a male with co-morbidity with plasma TIMP-1 and CEA co-ordinates to the right of the solid blue line would be
positive for the test. A female with or without co-morbidity and with plasma TIMP-1 and CEA co-ordinates to the right of the solid red or the
dotted red line, respectively, would be considered positive for the test. CEA: Carcinoembryonic antigen; TIMP-1: Tissue inhibitor of
metalloproteinases-1.
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